Amelioration of collagen-induced arthritis and suppression of interferon-?, interleukin-12, and tumor necrosis factor ? production by interferon-? gene therapy
Open Access
- 1 January 1999
- journal article
- basic science
- Published by Wiley in Arthritis & Rheumatism
- Vol. 42 (1) , 90-99
- https://doi.org/10.1002/1529-0131(199901)42:1<90::aid-anr12>3.0.co;2-a
Abstract
Objective To investigate the therapeutic effects and possible mechanisms of action of constitutive expression of interferon‐β (IFNβ) by syngeneic fibroblasts from DBA/1 mice in the collagen‐induced arthritis (CIA) model. Methods Immortalized embryonic DBA/1 fibroblasts were infected with a retrovirus expressing murine IFNβ. IFNβ‐expressing fibroblasts were then implanted intraperitoneally into mice immunized with bovine type II collagen. The effect of IFNβ on paw swelling, anticollagen antibody levels, IgG1/IgG2a isotype profiles, arthritis score, histologic joint damage, and cytokine secretion from lymph node cells and from bone marrow–derived macrophages was assessed. Results A single injection of IFNβ‐secreting fibroblasts was sufficient to prevent arthritis or to ameliorate existing disease. Thus, IFNβ reduced the clinical score and paw swelling irrespective of whether the injection was administered before or after disease onset in treated mice, compared with that in the untreated control group (P < 0.05). Histologic findings in the IFNβ‐treated mice were markedly less severe than in the control group (P < 0.001). This effect was accom‐panied by a decrease in total anticollagen IgG levels, a decrease in anticollagen IgG2a, and an increase in IgG1. In vitro, supernatants from these engineered fibroblasts inhibited collagen‐induced interferon‐γ secretion from lymph node cells, and reduced the levels of tumor necrosis factor α and interleukin‐12 produced by lipopolysaccharide/IFNγ‐treated bone marrow–derived macrophages. This effect was specific, since it was reversed with anti‐IFNβ polyclonal antibodies. Conclusion These results indicate that IFNβ, which is currently used as a treatment for relapsing, remitting multiple sclerosis, is a potent immunomodulatory and antiinflammatory cytokine in CIA and should be considered for the treatment of rheumatoid arthritis.Keywords
This publication has 33 references indexed in Scilit:
- Gene Therapy for Rheumatoid ArthritisDrugs & Aging, 1998
- Attenuation of collagen‐induced arthritis in mice by treatment with vector cells engineered to secrete interleukin‐13European Journal of Immunology, 1996
- Type 1 Interferon as an Antiinflammatory Agent: Inhibition of Lipopolysaccharide-Induced Interleukin-lβ and Induction of Interleukin-1 Receptor AntagonistJournal of Interferon & Cytokine Research, 1995
- CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3.The Journal of Experimental Medicine, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Interferon β decreases T cell activation and interferon γ production in multiple sclerosisJournal of Neuroimmunology, 1993
- Interferon-β specifically inhibits interferon-γ-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell lineJournal of Neuroimmunology, 1991
- EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERONPublished by Elsevier ,1987
- Efficient Constitutive Production of Human Fibroblast Interferon by Hamster Cells Transformed with the IFN-β1Gene Fused to An SV40 Early PromoterDNA, 1984
- Enhanced NK cell activity in mice injected with interferon and interferon inducersNature, 1978